National Bank of Canada FI Purchases 69,090 Shares of Hologic, Inc. (NASDAQ:HOLX)

National Bank of Canada FI grew its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 36.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 260,002 shares of the medical equipment provider's stock after acquiring an additional 69,090 shares during the quarter. National Bank of Canada FI owned 0.12% of Hologic worth $18,749,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in HOLX. Brooklyn Investment Group boosted its holdings in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock worth $82,000 after buying an additional 145 shares during the last quarter. Smartleaf Asset Management LLC grew its position in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC raised its stake in Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock valued at $602,000 after purchasing an additional 169 shares in the last quarter. UMB Bank n.a. grew its stake in Hologic by 4.1% in the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock worth $343,000 after buying an additional 188 shares in the last quarter. Finally, Capital Investment Counsel Inc raised its position in Hologic by 3.6% during the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock valued at $413,000 after purchasing an additional 200 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on HOLX shares. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a report on Tuesday, December 10th. Wolfe Research assumed coverage on Hologic in a research report on Friday, December 13th. They issued a "peer perform" rating for the company. William Blair reissued an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Raymond James reissued an "outperform" rating and set a $90.00 price objective (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Finally, Morgan Stanley lowered their price objective on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $84.62.

Hologic Price Performance

Shares of HOLX stock traded up $0.85 on Wednesday, hitting $59.31. 4,497,507 shares of the stock traded hands, compared to its average volume of 1,887,830. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a 52 week low of $57.38 and a 52 week high of $84.67. The firm has a 50 day simple moving average of $63.03 and a two-hundred day simple moving average of $71.87. The firm has a market cap of $13.31 billion, a price-to-earnings ratio of 18.71, a PEG ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.